All In Biotech

Drug Trial Radar · NCT06087796

Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.

Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata: a Clinical and Dermoscopic Study.

Last checked: Nov 19, 2026Latest source record: Oct 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 2023

Primary completion

Sep 2024

Study completion Oct 2024

Sponsor

Lead sponsor
Assiut UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy and safety of topical pentoxifylline 2% gel and topical metformin 10% gel versus topical betamethasone valerate 0.1% cream, in treatment of patchy alopecia areata.

Conditions

  • Alopecia Areata

Interventions

  • Betamethasone Valerate 0.1% CreamDrug

    Topical treatment modality for alopecia areata.

  • PentoxifyllineDrug

    Topical treatment modality for alopecia areata.

  • MetforminDrug

    Topical treatment modality for alopecia areata.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of hair regrowth in alopecia areata using SALT score.Time frame: 8 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Assiut university

    Asyut, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.